



**DEPARTMENT OF HEALTH & HUMAN SERVICES**

Public Health Service

Drug Administration

Food and

Rockville

MD 20857

NDA 21-066

Ciba Vision - A Novartis Company  
Attention: Lawrence D. Mandt  
Director, US Regulatory & Medical Affairs  
11460 Johns Creek Parkway  
Duluth, GA 30097

Dear Mr. Mandt:

Please refer to your new drug application (NDA) dated December 31, 1998, received January 4, 1999, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Zaditor (ketotifen fumarate ophthalmic solution) 0.025%.

We acknowledge receipt of your submissions dated February 1, 3 (two), 5, 9, 10, 15, 18, 22, 24, and 26; March 4, 5, 10, 17, and 25; April 2, 21, 26, and 30; May 5 (two), 14, 17, 18 and 24; June 4, 21 and 30; and July 1(two), 1999.

This new drug application provides for the use of Zaditor (ketotifen fumarate ophthalmic solution) 0.025% for the prevention of itching of the eye due to allergic conjunctivitis.

We have completed the review of this application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the enclosed labeling text. Accordingly, the application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical in content to the submitted package insert dated July 1, 1999. Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this

submission should be designated "FPL for approved NDA 21-066." Approval of this submission by FDA is not required before the labeling is used.

We remind you of the Phase 4 commitment specified in your submission dated June 21, 1999. This commitment is for the submission of a final study report of a clinical pharmacokinetic study to determine the systemic absorption of ketotifen after dosing with ketotifen fumarate ophthalmic solution 0.025%. Protocols, data, and the final report should be submitted to your IND for this product and a copy of the cover letter sent to this NDA. The study report should be submitted to the IND on or before January 1, 2000. For administrative purposes, all submissions, including labeling supplements, relating to this Phase 4 commitment must be clearly designated "Phase 4 Commitments."

Validation of the regulatory methods has not been completed. At the present time, it is the policy of the Center not to withhold approval because the methods are being validated. Nevertheless, we expect your continued cooperation to resolve any problems that may be identified.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please send one copy to the Division of Anti-Inflammatory, Analgesic and Ophthalmic Drug Products and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-40  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, contact Raphael R. Rodriguez, Project Manager, at (301) 827-2090.

Sincerely,

Robert DeLap, M.D., Ph.D.  
Director  
Office of Drug Evaluation V  
Center for Drug Evaluation and Research

